Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
6-1-2017

Promising therapeutics of gastrointestinal cancers in clinical
trials
Lingling Du
Washington University School of Medicine in St. Louis

Zheng Che
University of Toledo

Andrea Wang-Gillam
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Du, Lingling; Che, Zheng; and Wang-Gillam, Andrea, ,"Promising therapeutics of gastrointestinal cancers in
clinical trials." Journal of Gastrointestinal Oncology. 8,3. . (2017).
https://digitalcommons.wustl.edu/open_access_pubs/9926

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Review Article
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Abstract: Many novel therapeutics are being developed for patients with cancers along the gastrointestinal
(GI) tract. These emerging agents are frequently classified by their biological targets such as tumor growth
pathways, tumor metabolism, microenvironment, etc. Some agents targeting cancer growth pathways are
based on existing clinically validated therapeutic targets, such as regorafenib for hepatocellular carcinoma
(HCC), while other agents focus on newly identified targets, such as FGFR fusions in cholangiocarcinoma.
Drugs modifying the immunosuppressive tumor microenvironment have emerged as an attractive area of
clinical investigation. Moreover, drugs targeting the stem-cell like qualities of cancer and the tight junction
protein claudin 18.2 have generated quite a lot of excitement in the field. In this paper, we will systemically
review the recent promising agents and therapeutic strategies in GI cancers.
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Introduction
Over the past few decades, the treatment paradigm of
gastrointestinal (GI) cancers has changed substantially.
Monoclonal antibodies targeting angiogenesis and the
epidermal growth factor receptor (EGFR) signaling pathway
have become standard treatments for advanced colorectal
cancers (CRCs) (1,2). Small molecule multikinase inhibitors
have also demonstrated survival benefit in patients with
refractory CRCs and hepatocellular carcinomas (HCCs) (3,4).
Most recently, immunotherapy has shown promising clinical
efficacy in multiple types of GI cancers (5,6). Although
chemotherapy remains the mainstay of treatments for the
majority of GI cancers, novel agents either as single agents
or in combination are being evaluated in clinical trials
at an accelerated pace. Here we review the major drugs
that have demonstrated promising therapeutic activity in
clinical trials. Immunotherapy is not a significant part of the
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discussion here as it is discussed in great detail in another
review in this issue.
Growth signaling pathway inhibitors
Inhibition of growth signaling pathways has traditionally
been a research hot spot for GI cancers, and it has achieved
significant success with the development and clinical
use of small molecule kinase inhibitors and monoclonal
antibodies (1,2,4). Strategies of inhibiting the growth factor
pathways include targeting cell surface receptors or their
downstream cellular cascades. Vascular endothelial growth
factor receptor (VEGFR), MET, c-kit, platelet-derived
growth factor receptor (PDGFR), and fibroblast growth
factor receptor (FGFR) are commonly targeted cell surface
receptors. Activation of these receptors stimulates various
downstream signaling pathways that promote tumor cell
proliferation and sustain cell survival. One of the pathways
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Figure 1 Commonly targeted growth factor signaling pathways.

commonly involved is the Raf-MEK-ERK mitogenactivated protein kinase (MAPK) cascade, in which activated
Raf kinases phosphorylate the downstream MEK kinases,
and the latter activate the extracellular signal-regulated
kinases (ERK), which lead to cell growth (Figure 1) (7).
Therapeutics targeting the above cell surface receptors
and the downstream Raf-MEK-ERK pathway have shown
some promising results in GI cancers in early phase clinical
studies.
Cabozantinib is a dual inhibitor of the cell surface growth
receptors VEGFR2 and MET. In a phase II study, patients
with advanced HCCs were treated with cabozantinib at
100 mg daily for 12 weeks as the lead-in stage (8). Patients
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who demonstrated partial response (PR) were continued on
the treatment, whilst those with stable disease (SD) were
randomized to continue receiving cabozantinib or placebo.
Among the 41 patients enrolled, half had received prior
sorafenib. Cabozantinib was frequently associated with
fatigue, diarrhea, hand-foot syndrome, nausea/vomiting, and
thrombocytopenia. Sixty percent of patients needed dose
reductions during the lead-in stage. The overall response
rate (ORR) was 5%, but 78% of patients had SD. The
median progression-free survival (PFS) was 4.4 months,
and the median overall survival (OS) was 15.1 months.
These results were encouraging given that historically,
the ORR and the median OS for untreated HCC patients
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who received sorafenib were only 2% and 10.7 months,
respectively (4). A phase III study evaluating cabozantinib
at a dose of 60 mg daily versus placebo in patients with
advanced HCC who have received prior sorafenib is
ongoing (NCT01908426).
Another multikinase inhibitor, regorafenib, targets
multiple cell surface growth signaling receptors including
VEGFR1-3, KIT, PDGFR, and FGFR. It has been
approved for the treatment of advanced CRC. Recent
data indicated that it is also effective in treating advanced
HCC. The phase III RESORCE study tested the efficacy
of regorafenib in patients with HCC who had progressed
on sorafenib. The results were presented at the European
Society for Medical Oncology (ESMO) World Congress
of Gastrointestinal Cancer 2016 (9). A total of 573 patients
were randomized 2:1 to receive regorafenib at 160 mg
for 3 weeks every 4-week cycle versus placebo. Severe
adverse events were experienced in 79.7% of patients
treated with regorafenib versus 58.5% of those received
placebo. Common adverse events of regorafenib included
hypertension, hand-foot syndrome, fatigue, and diarrhea.
Regorafenib significantly improved the ORR (10.6% vs.
4.1%; P=0005), PFS (3.1 vs. 1.5 months; HR 0.46; 95% CI:
0.37–0.56; P<0.001), and OS (10.6 vs. 7.8 months; HR 0.62;
95% CI: 0.50–0.78; P<0.001) compared to placebo. These
results are very encouraging and make regorafenib an
attractive agent for HCC patients progressed on sorafenib.
Similar to regorafenib, nintedanib is also a multikinase
inhibitor targeting VEGFR1–3, FGFR, and PDGFR, but
with a better toxicity profile. In a phase I study, 30 patients
with previously treated advanced CRC were treated with
nintedanib (10). This was a heavily pretreated population
with prior lines of treatment ranging from 1–5. Nintedanib
was well tolerated with the most common adverse events
being mild nausea, vomiting, and diarrhea. Only 10% of
patients had ≥ grade 3 toxicities. Twenty-four patients (80%)
had SD for ≥8 weeks, and one patient had PR. Compared
to regorafenib, which provided a SD rate of 40% and a PR
rate of 1% but caused ≥ grade 3 toxicities in more than
half of patients (3), nintedanib was much better tolerated
and seemed to be quite active in refractory CRCs. The
phase III LUME-Colon 1 trial is comparing nintedanib
with placebo in patients with previously treated metastatic
CRC (NCT02149108). This study has finished accrual
of 764 patients and was estimated to be completed in
December 2016.
There has been quite a lot of excitement in targeting
FGFR, particularly in cholangiocarcinoma. The FGFR
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family consists of four receptors that are activated by
binding fibroblast growth factors using heparin or heparin
sulfate proteoglycan as a co-factor (11). Activated FGFR
triggers complex downstream pathways including the
phosphoinositide 3-kinase (PI3K)-AKT cascades and the
Raf-MEK-ERK signaling pathway. FGFR2 fusions have
been identified in approximately 13% of intrahepatic
cholangiocarcinomas (12,13). Preliminary efficacy of
FGFR inhibitors has been demonstrated in patients with
FGFR2 fusion and preclinical models (14,15). A phase
II study examined the activity of a pan-FGFR inhibitor,
BGJ398, in patients with previously treated advanced
cholangiocarcinoma harboring FGFR2 alterations (16).
Forty-seven patients received the study drug. FGFR2
translocations were found in 38 patients, with FGFR2BICC1 fusions being the most common (n=9). Nine patients
had other FGFR alterations, including mutations in FGFR
and amplifications in FGFR2 and FGFR3. This was a
heavily pretreated patient population, with 62% of patients
receiving ≥2 prior lines of therapies, and 11% with ≥4 prior
regimens. Adverse events were overall manageable, with
hyperphosphatemia, fatigue, constipation, and diarrhea
being the most common. Among a total of 36 evaluable
patients, eight patients (22%) had PR and 19 (53%) had
SD. Median duration of drug exposure was 188 days. These
results were encouraging when compared to the median
PFS of approximately 3 months in patients who received
second-line therapies for advanced cholangiocarcinoma
(17,18). Several clinical studies are ongoing to test the role
of other FGFR inhibitors in cholangiocarcinomas or other
solid tumors harboring FGFR alterations (NCT02834780,
NCT01752920).
Moving from the cell surface receptors to downstream
signaling cascades, the Raf-MEK-ERK signaling pathway
is frequently involved in carcinogenesis. The BRAF gene
encodes an intracellular Raf protein, which upon activation,
phosphorylates and triggers sequential activation of the
MEK/ERK protein cascade. BRAF mutations occurred in
approximately 12% of CRCs (19). Patients with metastatic
BRAF-mutant CRCs have a worse survival compared to
their BRAF wild type counterparts, with a median survival
of approximately one year (20). In contrast to the potent
activity of the BRAF inhibitor vemurafenib in melanoma,
single-agent vemurafenib failed in a phase II study of
patients with metastatic BRAF-mutated CRCs, with an
ORR of 5% and a median PFS of 2.1 months (21). This
indicated that the BRAF inhibition alone might not be
sufficient in treating BRAF-mutant CRCs, and combination
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therapy might be a better treatment approach. In a phase
II study, investigators examined the combination of a
BRAF inhibitor, encorafenib, and the anti-EGFR antibody,
cetuximab, with or without the PI3Kα inhibitor, alpelisib,
in patients with previously treated advanced CRCs that
are BRAF-mutated (22). A total of 102 patients were
randomized to the triplet versus the doublet arm. Grade
3–4 adverse events including anemia, hyperglycemia,
and elevated lipase were more common in the triplet
arm. The ORR was 27% for the triplet arm versus 22%
for the doublet arm. Both median PFS (5.4 months for
triplet versus 4.2 months for doublet; HR 0.8; 95% CI:
0.5–1.2; P=0.14) and median OS were similar between the
two arms (13.1 months for triplet versus 12.4 months for
doublet; HR 1.1; 95% CI: 0.6–2.0). The median OS in this
study was much better compared to the historical OS of
approximately 6 months for this patient population (23,24),
but the survival benefit needs to be confirmed in phase III
clinical trials. Furthermore, whether the survival benefit
with additional alpelisib outweighs the increased toxicities
awaits further examination in future studies.
Further down the Raf-MEK-ERK pathway, small
molecule kinase inhibitors targeting the MEK protein, such
as cobimetinib and trametinib, have prolonged survival in
patients with BRAF-mutant melanoma (25,26). Ongoing
efforts are examining the role of MEK inhibitors in CRC.
A phase Ib study tested the combination of cobimetinib
with the PD-L1 inhibitor atezolizumab in patients with
microsatellite stable CRCs. Single agent PD-1 blockade
does not appear to have significant anti-tumor activity
in microsatellite stable tumors (5). Inhibiting MEK with
cobimetinib upregulates the major histocompatibility
complex (MHC) class I on tumor cells, enhances
intratumoral T cell filtration, and increases the activity
of atezolizumab (27). In this study, a total of 23 patients
received cobimetinib and atezolizumab (28). This was a
heavily pretreated patient population, with a median of
three lines of prior therapies. The microsatellite status was
stable in 30% of patients and unknown in the other 70%.
There were no dose-limiting toxicities (DLTs) observed
with the maximum dose of cobimetinib at 60 mg daily. The
most common adverse events included diarrhea, fatigue,
rash, pruritus, and nausea. One third of patients experienced
grade 3 toxicities, with diarrhea being the most common.
But there were no grade 4 or 5 toxicities. The ORR was
17%, and the duration of response was not reached (range,
5.4 to 11.1+ months) by the time results were presented.
The 6-month PFS and OS rates were 35% and 72%,
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respectively. Again, compared to the historical ORR of 1%
and median PFS of approximately 2 months in patients
with refractory CRCs, these results looked extremely
promising (3). Based on these data, a phase III study
investigating the activity of cobimetinib plus atezolizumab
in patients with chemotherapy-refractory advanced CRCs is
ongoing (NCT02788279).
Targeting the tumor microenvironment
The tumor microenvironment is a complex network
comprised of extracellular matrix (ECM) and a myriad of
immune cells. It serves as a mechanical and biochemical
barrier that shields off the delivery and/or attenuates
the antitumor effect of drugs, and more importantly,
creates an immunosuppressive environment that impedes
tumor immune response. Drugs targeting the tumor
microenvironment have been aimed at different facets of the
network, including the pro-tumorigenic cytokine signaling
pathways such as transforming growth factor-β (TGF-β) and
CC chemokine ligand 2-CC chemokine receptor 2 (CCL2CCR2), enzymes or transmembrane proteins that modulate
T cell activities such as indoleamine-2,3-dioxygenase (IDO)
and CD40, and the mechanical component of the tumor
stroma such as hyaluronan (HA).
The TGF-β cytokine is secreted by tumors and, in
turn, facilitates tumor progression and invasion. TGF-β
upregulates VEGF and promotes angiogenesis, suppresses
the antitumor effect of T cells and natural killer (NK) cells,
and stimulates the production of metalloproteinases (MMPs)
that degrade ECM and facilitate tumor invasion (29). The
TGF-β receptor-1 kinase inhibitor galunisertib was tested
in a phase II study in patients with advanced HCC who had
progressed on or were ineligible for sorafenib (30). A total
of 109 HCC patients with Child Pugh A or B7 disease were
randomized to receive galunisertib at 160 or 300 mg/day
on a 2-week on, 2-week off schedule. Twenty-four percent
of patients had a reduction in serum alpha fetoprotein
(AFP) levels by >20% from baseline. The median time-toprogression (TTP) and OS were 2.8 and 8.3 months in the
overall population, and 4.3 and 21.4 months in the AFP
responders, respectively. Galunisertib was well tolerated at
both dose levels. Neutropenia, fatigue, and anemia were the
most common grade 3–4 adverse events. The 300 mg/day
dose was found to confer better drug exposure, and it was
selected for future studies. Another phase II study tested
galunisertib in patients with advanced HCC but low serum
AFP levels (31). The majority of patients had received
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prior sorafenib. Twenty-nine out of 40 patients treated
with galunisertib had a reduction in serum TGF-β levels
by >20%. In patients with a TGF-β reduction >20%, the
median OS was 21.8 months, compared to 7.9 months
in those without a TGF-β response. Combinations of
galunisertib and immunotherapy are being evaluated in
patients with HCC (NCT02423343) and pancreatic cancer
(NCT02734160). The incorporation of galunisertib into
neoadjuvant chemoradiotherapy is also being explored
in locally advanced rectal cancer in a phase II study
(NCT02688712).
The CCL2-CCR2 chemokine signaling pathway has been
avidly studied as a target for anticancer therapies. Tumors
and stromal cells synthesize the CCL2 ligand, which recruits
CCR2-positive inflammatory monocytes to the tumors,
where they can differentiate into immunosuppressive
t u m o r- a s s o c i a t e d m a c r o p h a g e s ( TA M s ) ( 3 2 , 3 3 ) .
TAMs play an important role in mediating tumor immune
evasion and promoting tumor progression and invasion
(34,35). High CCL2 expression and low CD8+ T cell
infiltrates in the tumors was associated with decreased
survival in patients who underwent resection of pancreatic
cancers (36). A phase Ib study tested the combination of
the CCR2 inhibitor PF-04136309 with FOLFIRINOX
in patients with borderline resectable or locally advanced
pancreatic cancers. This combination regimen resulted in
an ORR of 49% and a disease control rate of 97% (37). PF04136309 was generally well tolerated. These results looked
promising in light of the ORR of 32% and the disease control
rate of 70% with FOLFIRINOX alone (38). A phase I study
testing the combination of PF-04136309 with gemcitabine
and nab-paclitaxel in pancreatic cancer is ongoing
(NCT02732938). Another CCR2 inhibitor, CCX872-B,
is being tested in a phase Ib study in combination with
FOLFIRINOX in patients with advanced pancreatic cancers
(NCT02345408).
Apart from the chemokine signaling pathways, T cells
are also major components of the tumor microenvironment
and are critical in tumor-specific immune responses. Most
tumors evade this immune surveillance by a plethora of
mechanisms, one of which being the IDO pathway. IDO
is the key enzyme in the catabolism of tryptophan that is
critical in the differentiation and proliferation of T cells.
Both tumors and antigen-presenting cells (APCs) express
IDO, which suppresses tumor-specific cytotoxic T cells
and enhances the activity of immunosuppressive regulatory
T cells (39). In a breast cancer mouse model, an IDO
inhibitor in combination with paclitaxel synergistically
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induced tumor regression (40). A phase I/II study examined
the combination of an IDO inhibitor, indoximod, with
gemcitabine and nab-paclitaxel in patients with metastatic
pancreatic cancer. In this study, five out of 12 patients
achieved an objective response (42%), including one patient
with a complete response (41). The combination was well
tolerated, with common side effects being fatigue, weight
loss, diarrhea, and peripheral edema. An interim analysis
of the phase II part of this study continued to confirm
the efficacy, with 11 out of 30 patients demonstrating an
objective response (37%) (42). Given that the ORR with
gemcitabine plus nab-paclitaxel was 23% (43), incorporating
indoximod into this regimen may provide additional clinical
benefits. This study remains ongoing to further examine
the role of indoximod in the treatment of pancreatic cancers
(NCT02077881).
Another means to activate cytotoxic T cells is via the
ligation of the transmembrane protein CD40. CD40 is a
member of the tumor necrosis factor (TNF) superfamily. It
is widely expressed on APCs and a variety of tumors (44,45).
Ligation of CD40 on APCs orchestrates the priming and
activation of tumor-specific cytotoxic T cells and eradicates
tumors (46,47). CD40 ligation on carcinoma cells also
upregulates the expression of Fas and TNF in these cells
and induces apoptosis (48). A phase I study examined the
combination of an agonist CD40 monoclonal antibody,
CP-870,893, with gemcitabine in patients with untreated
advanced pancreatic cancers (49). Four out of 22 patients
achieved a PR (18%). The combination was generally welltolerated, with mild cytokine release syndrome, fatigue,
and cytopenia being the most common adverse events.
Phase I studies are ongoing to evaluate several CD40
agonistic antibodies either alone or in combination with
immunotherapy in patients with solid tumors. Other
CD40 antibodies under investigation include APX005M
(NCT02482168), SEA-CD40 (NCT02376699), and
RO7009789 (NCT02665416, NCT02304393).
Besides the signaling pathways that modify immune
responses, the tumor stroma itself can also be a therapeutic
target. This is particularly important in pancreatic cancer,
which is surrounded by a desmoplastic stroma enriched with
HA. There was some preclinical evidence suggesting that
HA stimulated pancreatic cancer cell migration (50). High
expressions of HA in the tumors were associated with shorter
survival in patients with resected pancreatic cancer (51).
A PEGylated recombinant human hyaluronidase,
PEGPH20, depletes HA and was tested in a randomized
phase II trial (52). In this study, patients with untreated
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metastatic pancreatic cancers were randomly assigned to
receive nab-paclitaxel plus gemcitabine with or without
PEGPH20. A total of 135 patients received at least one
dose of the study drugs. In all patients, the ORR (with
vs. without PEGPH20: 41% vs. 34%; P=0.48) and PFS
(with vs. without PEGPH20: 5.7 vs. 5.2 months; P=0.11)
were similar. However, in those with high expressions of
HA, the ORR was better in the PEGPH20 arm (52% vs.
24%; P=0.038). The PEGPH20 arm also showed a trend
towards longer PFS (9.2 vs. 4.3 months; HR 0.39; 95%
CI: 0.15–1.04; P=0.05) and better OS (12 vs. 9 months;
HR 0.62; 95% CI: 0.26–1.46). The PEGPH20 group
experienced more thromboembolic events, peripheral
edema, muscle spasms, and neutropenia, but these toxicities
were manageable and the incidence of thromboembolic
events decreased substantially after prophylactic enoxaparin
was implemented. A phase III study evaluating the efficacy
of PEGPH20 in combination with nab-paclitaxel and
gemcitabine in patients with HA-high metastatic pancreatic
cancers is ongoing (NCT02715804).

529

II FAST trial, patients with CLDN18.2-positive advanced
gastric or gastroesophageal junction (GEJ) cancers were
randomized 1:1 to receive epirubicin, oxaliplatin, and
capecitabine (EOX) with or without IMAB362 (58). A
total of 161 patients were randomized. IMAB362 plus
chemotherapy significantly improved the median PFS
(7.9 vs. 4.8 months; HR 0.47; 95% CI: 0.31–0.70; 1-sided
P=0.0001) and OS (13.2 vs. 8.4 months; HR 0.51; 95%
CI: 0.36–0.73; P=0.0001). Moreover, IMAB362 seemed
to be more beneficial in those who had high expressions of
CLDN18.2, defined as 2+ or 3+ CLDN18.2 expression in
≥70% of tumor cells. In these patients, the median OS with
and without IMAB362 were 16.7 and 9.0 months (HR 0.45;
P≤0.0005), respectively. Also of note, in this study, patients
treated with EOX alone only had a median OS of 8.4 months,
which was inferior to the median OS of 11.2 months with
EOX in the REAL-2 trial (59). Incorporating IMAB362
with a better chemotherapy backbone may be worthy of
investigation in future clinical studies.
Conclusions

Cancer stemness inhibitor
Cancer stem cells are referred to the subpopulations
of cancer cells harboring extremely high potential for
tumorigenesis and have been isolated from various GI
cancers (53-55). Napabucasin (BBI-608) is a first-in-class
cancer stemness inhibitor that targets Stat3-dependent
gene transcription. In a phase Ib study, napabucasin was
tested in combination with FOLFIRI and bevacizumab in
patients with advanced CRCs (56). A total of 46 patients
were enrolled and randomized to receive napabucasin plus
FOLFIRI with or without bevacizumab. There were no
DLTs observed in the study, and the most common grade
3 adverse events were diarrhea and fatigue. An objective
response was achieved in 13 of the 40 evaluable patients
(33%). Furthermore, among the 14 evaluable patients who
were previously refractory to FOLFIRI, three achieved PR
(25%). These results are intriguing and suggest that a cancer
stemness inhibitor may re-sensitize refractory patients to
chemotherapy. A phase III study of napabucasin is ongoing
in patients with advanced CRCs (NCT02753127).
Other novel targets for GI cancer treatment
IMAB362 is a first-in-class monoclonal antibody against the
tight junction protein claudin 18.2 (CLDN18.2), which is
frequently expressed on gastric cancers (57). In the phase
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Novel drugs targeting various antitumor mechanisms of GI
cancers are under rapid development (Table 1). Inhibitors
targeting growth factor pathways have shown encouraging
results in early phase studies. By targeting cell surface
receptors, the multikinase inhibitors cabozantinib and
regorafenib have demonstrated significant clinical activity
in advanced HCCs, and both are being tested in phase III
studies. FGFR inhibitors may alter the treatment paradigm
of cholangiocarcinoma with FGFR translocations. Agents
targeting different levels of the cellular Raf-MEK-ERK
signaling pathway are also being tested in GI cancers.
In BRAF mutant CRCs, the combination of the BRAF
inhibitor encorafenib and cetuximab has demonstrated
promising efficacy and warrants further study in phase III
trials. The MEK inhibitor cobimetinib seems to enhance
the antitumor activity of PD-L1 inhibitor in patients
with microsatellite stable CRCs. Drugs that modify the
immunosuppressive tumor microenvironment seem to be
active against GI cancers, but may need to be combined
with other drugs such as chemotherapy or immunotherapy
to enhance the antitumor effect. These agents include
the TGF-β inhibitor galunisertib, CCR2 inhibitors PF04136309 and CCX872-B, the IDO inhibitor indoximod,
the CD40 agonizing antibody CP-870,893, and the
recombinant hyaluronidase PEGPH20. Last but not least,
drugs aimed at novel targets are breaking new ground in the
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TGF-β inhibitor

TGF-β inhibitor

TGF-β inhibitor

CCR2 inhibitor

CCR2 inhibitor

Hyaluronidase

Galunisertib

Galunisertib

Galunisertib

PF-04136309

CCX872-B

PEGPH20

CLDN18.2 inhibitor

Epirubicin + capecitabine + oxaliplatin + IMAB362

FOLFIRI +/− napabucasin. Bevacizumab allowed in
both arms

Gemcitabine + nab-paclitaxel +/− PEGPH20

CCX872-B + FOLFIRINOX

PF-04136309 + gemcitabine + nab-paclitaxel

Galunisertib + fluorouracil-based chemoradiotherapy
+ surgery

Galunisertib + nivolumab

Galunisertib + durvalumab

Cobimetinib + atezolizumab vs. atezolizumab vs.
regorafenib

Encorafenib + cetuximab +/− PI3Kα inhibitor alpelisib

BGJ398

Nintedanib vs. placebo

Regorafenib vs. placebo

Cabozantinib vs. placebo

Study arms

CLDN18.2+ gastric cancer

CRC

Hyaluronan-high pancreatic
cancer

Pancreatic cancer

Pancreatic cancer

Rectal cancer

HCC

Pancreatic cancer

CRC

BRAF mutant CRC

Cholangiocarcinoma

CRC

HCC

HCC

Disease type

II

III

III

Ib

I

II

I/II

I

III

II

II

III

III

III

Phase

01630083

02753127

02715804

02345408

02732938

02688712

02423343

02734160

02788279

01719380

02150967

02149108

01774344

01908426

NCT

Multi, multikinase inhibitor; VEGFR, vascular endothelial growth factor receptor; vs., versus; HCC, hepatocellular carcinoma; PDGFR, platelet-derived growth factor
receptor; FGFR, fibroblast growth factor receptor; CRC, colorectal cancer; TGF-β, transforming growth factor-β; CCR2, CC chemokine receptor 2; CLDN18.2, claudin 18.2.

IMAB362

Cancer stemness inhibitor

MEK inhibitor

Cobimetinib

Napabucasin

BRAF inhibitor

Encorafenib

Multi: VEGFR1–3, PDGFR, FGFR

Nintedanib

FGFR inhibitor

Multi: VEGFR1–3, KIT, PDGFR, FGFR

Regorafenib

BGJ398

Multi: MET, VEGFR2

Mechanism

Cabozantinib

Drug

Table 1 Promising therapeutics in clinical trials
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treatment of GI cancers. The first-in-class cancer stemness
inhibitor napabucasin in combination with chemotherapy
has shown encouraging activity in patients with advanced
CRCs and may overcome the problem of chemotherapy
refractoriness in those who are heavily pretreated. In
addition, the CLDN18.2 inhibitor IMAB362 is active
against CLDN18.2-positive gastric cancers. Selecting the
correct patient population and incorporating IMAB362
with better chemotherapy regimens would be the key for
future studies.
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